Table 1.
Patient demographics from KEM and HH cohorts.
| Characteristics | KEM (n = 323) | HH (n = 224) | P value | |
|---|---|---|---|---|
| Age years (%) | <60 | 160 (49.5) | 97 (43.4) | ns |
| >60 | 163 (50.0) | 127 (56.7) | ||
| FIGO stage (%) | I | 6 (1.9) | 9 (4) | <0.0001 |
| II | 14 (4.3) | 16 (7.1) | ||
| III | 132 (40.9) | 135 (60.3) | ||
| IV | 166 (51.4) | 61 (27.2) | ||
| Unknown | 5 (1.5) | 3 (1.3) | ||
| ECOG (%) | 0 | 297 | 11 | <0.0001 |
| 1 | 20 | 31 | ||
| 2 | 5 | 18 | ||
| 3 | 1 | 2 | ||
| Unknown | – | 162 | ||
| BRCA status | BRCA1/2 mut | 99 | – | |
| Wild-type | 73 | – | ||
| Unknown | 151 | 224 | ||
| Residual disease (%) | Tumour-free | 196 (60.7) | 106 (47.3) | ns |
| Non-tumour-free | 122 (37.8) | 47 (21) | ||
| Unknown | 5 (1.5) | 71 (31.7) | ||
| RPV | Low | 175 | 147 | 0.00253 |
| Medium | 108 | 66 | ||
| High | 40 | 11 | ||
| Follow-up (months; median IQR) | 34.5 (13.1–54.4) | 49.3 (16.5–71.8) | ns | |
| PFS (months; median IQR) | All | 23.9 (16.2–49.7) | 21.1 (11.7–50.9) | ns |
| Stage III | 26.60 (17.50–49.80) | 19.41 (12.36–41.28) | 0.0312 | |
| Stage IV | 21.20 (13.30–31.60) | 13.54 (8.89–37.25) | ns | |
| OS (months; median IQR) | All | 53.2 (24.7–NR) | 51.8 (25.5–NR) | ns |
| Stage III | 59.10 (27.20–NR) | 53.15 (25.97–85.08) | ns | |
| Stage IV | 37.40 (19.70–57.50) | 33.51 (19.08–53.05) | ns | |
| Relapsed (%) | No | 167 (51.7) | 96 (42.9) | ns |
| Yes | 156 (48.3) | 108 (48.2) | ||
| Unknown | – | 20 (8.9) | ||
| Deceased (%) | No | 211 (65.3) | 133 (59.4) | ns |
| Yes | 112 (34.7) | 90 (40.2) | ||
| Unknown | – | 1 (0.4) |